Table 1.
Baseline characteristics of patients
| Did not undergo 2yr Biopsy |
Underwent 2 yr Biopsy | p-value | |
|---|---|---|---|
| Number of Patients, n (%) | 1,599 (20) | 6,463 (80) | - |
| Baseline Age, mean (SD) | 62.8 (6.3) | 62.7 (6.0) | - |
| <65, n (%) | 924 (19) | 3849 (81) | 0.065† |
| 65-69, n (%) | 407 (19) | 1681 (81) | |
| ≥70, n (%) | 268 (22) | 933 (78) | |
| Race, n (%) | <0.001† | ||
| White | 1432 (19) | 5911 (81) | |
| Black | 59 (32) | 122 (68) | |
| Other | 107 (20) | 430 (80) | |
| Missing | 1 (100) | 0 (0) | |
| Region, n (%) | <0.001† | ||
| North America | 485 (23) | 1596 (77) | |
| Europe | 929 (19) | 3951 (81) | |
| Other | 185 (17) | 916 (83) | |
| Center Volume, n (%) | <0.001† | ||
| 1st tertile (0-10 subjects) | 614 (25) | 1872 (75) | |
| 2nd tertile (11-25 subjects) | 489 (18) | 2271 (82) | |
| 3rd tertile (>25 subjects) | 496 (18) | 2320 (82) | |
| BMI, n (%) | 0.063† | ||
| <25 | 394 (19) | 1726 (81) | |
| 25-29.9 | 845 (20) | 3333 (80) | |
| ≥30 | 324 (20) | 1309 (80) | |
| Missing | 36 (27) | 95 (70) | |
| PSA, n (%) | 0.026† | ||
| 1st tertile | 551 (21) | 2066 (79) | |
| 2nd tertile | 501 (19) | 2195 (81) | |
| 3rd tertile | 540 (20) | 2191 (80) | |
| Missing | 7 (39) | 11 (61) | |
| Prostate Volume, n (%) | 0.004† | ||
| 1st tertile | 533 (20) | 2119 (80) | |
| 2nd tertile | 503 (19) | 2149 (81) | |
| 3rd tertile | 528 (20) | 2125 (80) | |
| Missing | 35 (33) | 70 (67) | |
| DRE, n (%) | 0.032† | ||
| Normal/enlarged | 1535 (20) | 6213 (80) | |
| Abnormal | 57 (19) | 242 (81) | |
| Missing | 7 (47) | 8 (53) | |
| IPSS Score, n (%) | 0.004† | ||
| 0-7 (“Mild”) | 701 (19) | 3066 (81) | |
| 8-19 (“Moderate”) | 733 (20) | 2840 (80) | |
| 20-35 (“Severe”) | 91 (26) | 258 (74) | |
| Missing | 74 (20) | 299 (80) | |
| # of Medications Reported, n (%) | 0.041† | ||
| No medications | 507 (22) | 1838 (78) | |
| 1-5 | 949 (19) | 4077 (81) | |
| 6-10 | 139 (21) | 527 (79) | |
| >10 | 4 (16) | 21 (84) | |
| Diabetes Mellitus Reported, n (%) | 0.070† | ||
| No | 1440 (20) | 5933 (80) | |
| Yes | 159 (23) | 529 (77) | |
| Missing | 0 (0) | 1 (100) | |
| Hypertension Reported, n (%) | 0.780† | ||
| No | 989 (20) | 3999 (80) | |
| Yes | 610 (20) | 2469 (80) | |
| Missing | 0 (0) | 2 (100) | |
| CAD Reported, n (%) | 0.644† | ||
| No | 1464 (20) | 5946 (80) | |
| Yes | 135 (21) | 515 (79) | |
| Missing | 0 (0) | 2 (100) | |
| Smoking Status, n (%) | 0.214† | ||
| Never | 718 (19) | 2971 (81) | |
| Former | 612 (19) | 2540 (81) | |
| Current | 268 (22) | 947 (78) | |
| Missing | 1 (17) | 5 (83) | |
| Reported Alcohol Use, n (%) | 0.001† | ||
| Non-drinker | 471 (22) | 1624 (78) | |
| Moderate Drinker (0-7/wk) | 705 (18) | 3151 (82) | |
| Heavy Drinker (>7/wk) | 410 (20) | 1653 (80) | |
| Missing | 13 (27) | 35 (73) | |
| FHx Prostate Cancer, n (%) | 0.203† | ||
| No | 1410 (20) | 5607 (80) | |
| Yes | 187 (18) | 852 (82) | |
| Missing | 2 (33) | 4 (67) | |
| FHx Breast Cancer, n (%) | 0.117† | ||
| No | 1424 (20) | 5740 (80) | |
| Yes | 173 (19) | 722 (81) | |
| Missing | 2 (67) | 1 (33) |
Abbreviations: BMI, body mass index (kg/m2); CAD, coronary artery disease; DRE, digital rectal exam; FHx, reported family history of; IPSS, International Prostate Symptom Score.
P-value (bold)=Bonferroni corrections applied for statistically significant P-values (P=0.05/18=0.003).
P-value (italics)=Nominally statistically significant P-values (P<0.05).
a
Pearson Chi2.